BID | 4.92 | ASK | 5.09 | ||
Open | 4.95 | Previous Close | 5.00 | ||
Pre-Market | - | After-Market | 4.91 | ||
- - | -0.04 -0.81% |
Target Price | - | Analyst Rating | — — 0.00 | |
Potential % | - | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 57.22 | |
Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | ★★★★★ 67.47 | |
Price Range Ratio 52W % | 3.35 | Earnings Rating | — | |
Market Cap | 8.11M | Earnings Date | - | |
Alpha | -0.01 | Standard Deviation | 0.33 | |
Beta | 2.12 |
Today's Price Range 4.925.19 | 52W Range 4.4519.50 | 5 Year PE Ratio Range -1.60-0.8000 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -1.64% | ||
1 Month | 0.20% | ||
3 Months | -19.51% | ||
6 Months | -46.76% | ||
1 Year | -69.70% | ||
3 Years | -80.92% | ||
5 Years | -75.74% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -16.89 | |||
ROE last 12 Months | -14.50 | |||
ROA (5Y Avg) | -5.09 | |||
ROA last 12 Months | -8.74 | |||
ROC (5Y Avg) | -75.55 | |||
ROC last 12 Months | -11.73 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -5.87 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 3.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.10 | ||||
0.19 | ||||
0.23 | ||||
- | ||||
-2.60 | ||||
-3.21 | ||||
0.53 | ||||
27.54 | ||||
-1 833 900.00 | ||||
Forward PE | -1.04 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
1.40 | ||||
0.10 | ||||
0.32 | ||||
-9.70 | ||||
Leverage Ratio | 2.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
24.30 | ||||
-47.90 | ||||
-43.90 | ||||
-2 596.40 | ||||
-13.58 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
35.81M | ||||
21.85 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
15.59 | ||||
0.80 | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2022 FY | -6.45 | 0.00 | - |
12/2023 FY | -4.80 | 0.00 | - |
- | - | - | - |
- | - | - | - |
Next Report Date | - |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 8.72K |
Shares Outstanding | 1.64K |
Shares Float | 491.83M |
Trades Count | 98 |
Dollar Volume | 43.56K |
Avg. Volume | 30.31K |
Avg. Weekly Volume | 24.28K |
Avg. Monthly Volume | 15.24K |
Avg. Quarterly Volume | 51.42K |
Medigus Ltd. (NASDAQ: MDGS) stock closed at 4.95 per share at the end of the most recent trading day (a -1% change compared to the prior day closing price) with a volume of 8.72K shares and market capitalization of 8.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 26 people. Medigus Ltd. CEO is Liron Carmel.
The one-year performance of Medigus Ltd. stock is -69.7%, while year-to-date (YTD) performance is 6%. MDGS stock has a five-year performance of -75.74%. Its 52-week range is between 4.445 and 19.5, which gives MDGS stock a 52-week price range ratio of 3.35%
Medigus Ltd. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.19, a price-to-sale (PS) ratio of 0.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -8.74%, a ROC of -11.73% and a ROE of -14.50%. The company’s profit margin is -13.58%, its EBITDA margin is -43.90%, and its revenue ttm is $35.81 Million , which makes it $21.85 revenue per share.
Of the last four earnings reports from Medigus Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Medigus Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Medigus Ltd. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Medigus Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Medigus Ltd. has a dividend yield of 15.59% with a dividend per share of $0.80 and a payout ratio of -%.
Medigus Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.78, ATR14 : 0.36, CCI20 : 59.27, Chaikin Money Flow : -0.13, MACD : -0.06, Money Flow Index : 44.45, ROC : -0.20, RSI : 46.50, STOCH (14,3) : 56.20, STOCH RSI : 0.67, UO : 43.26, Williams %R : -43.80), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Medigus Ltd. in the last 12-months were:
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | - | - | - |
Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.
CEO: Liron Carmel
Telephone: +972 733704691
Address: 3 HaNechoshet Street, Tel Aviv 6971068, , IL
Number of employees: 26
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.